Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
In a prospective multicenter cohort, P85-Ab achieved 93.0% sensitivity and 97.3% specificity for suspected nasopharyngeal carcinoma, outperforming conventional EBV serologies in outpatient practice.
This review synthesizes the BRIGHT-2 trial findings and meta-analytical data, confirming that bireociclib plus fulvestrant significantly improves progression-free survival in HR+/HER2- advanced breast cancer.
In adults with myelodysplastic neoplasms undergoing allogeneic transplantation, pretransplant cytoreduction modestly improved IPSS-M in some patients but did not improve post-transplant survival and was associated with higher non-relapse mo
In advanced head and neck squamous cell carcinoma, pretreatment weight loss and low prognostic nutritional index were linked to shorter progression-free survival after immunotherapy, while baseline BMI was not predictive.
Pembrolizumab plus chemoradiotherapy improved survival and quality-adjusted survival for FIGO 2014 stage III-IVA cervical cancer and was projected to be cost-effective in the U.S. at a $150,000/QALY threshold.
A Gut study identifies MLCK1-driven epithelial barrier failure as a central mechanism in immune checkpoint inhibitor colitis and suggests epicatechin as a barrier-protective strategy that preserves antitumour efficacy in preclinical models.
Long-term phase 2 data suggest that 36 Gy preoperative radiotherapy for localized myxoid liposarcoma preserves excellent local control while limiting wound and late toxic effects.
A national database study found that neoadjuvant chemotherapy was linked to worse overall survival than upfront surgery in node-positive hormone receptor-positive, HER2-negative breast cancer, except in patients who achieved nodal complete
A major randomized trial found that chemotherapy before surgery did not improve 3-year disease-free survival in locally advanced colon cancer, but it still revealed important clues for more personalized treatment.
In occult breast cancer, clipped-node pathology after neoadjuvant therapy tracked residual axillary disease with high specificity, supporting limited axillary surgery in selected patients, especially those with cN1–cN2 disease.
KRAS mutation and high glucose promote O-GlcNAcylation of CLDN18.2 in pancreatic cancer, pushing the protein off the cell membrane, boosting metastasis, and weakening CLDN18.2-targeted therapy. Low-dose MRTX1133 may restore sensitivity.
In radioiodine-avid metastatic differentiated thyroid cancer, rhTSH and mixed rhTSH/thyroid hormone withdrawal preparation produced comparable adjusted outcomes. Prognosis was driven mainly by metastatic burden and age, supporting individua
This international study found that biopsy of pheochromocytoma and paraganglioma had low mortality and low serious complication rates, suggesting biopsy may be reasonable in carefully selected patients with expert management.
A UK Biobank study found that lifestyle-related pancreatic cancer risks were strongest in younger adults, especially those with high genetic risk, supporting early prevention efforts.
A phase 2 randomized trial found that 12 weeks of testosterone cypionate improved sexual activity, desire, mood, body composition, and exercise performance in hypogonadal men after radical prostatectomy, with no biochemical recurrence obser
A large real-world registry study shows that ovarian cancer patients aged 70 and older still carry clinically actionable germline variants, often without a reported family history, supporting broader age-inclusive genetic testing.
A large retrospective cohort shows that bilateral adrenal masses are usually benign and concordant, but asynchronous or discordant lesions identify a clinically important subgroup enriched for malignancy and pheochromocytoma.
A population-based study of older adults with metastatic NSCLC found that fewer than half received systemic treatment, with only slight improvement over time. Oncology referral and biomarker testing were strongly linked to treatment, while
A large SEER-Medicare study found that fewer than half of older adults with metastatic NSCLC received systemic therapy, with only modest improvement from 2006 to 2021. Specialist referral and biomarker testing were strongly linked to treatm
A PETHEMA registry study shows that specific mutations, especially DNMT3A, SF3B1, TP53, and WT1, meaningfully refine relapse-free survival after allo-HSCT in first-remission AML beyond ELN risk groups.
Open language-specific specialty feeds and department pages.